Caredx comments on issuance of proposed lcd for molecular testing for solid allograft rejection

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today commented on the issuance of proposed changes to the local coverage determination (lcd) moldx molecular testing for solid organ allograft rejection that covers allosure®, allomap® and heartcare. caredx is pleased that moldx is p.
CDNA Ratings Summary
CDNA Quant Ranking